Bulletin of the World Health Organization

Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial

Boubacar Nacro, Emmanuelle Zoure, Hervé Hien, Hassane Tamboura, François Rouet, Adama Ouiminga, Ali Drabo, Souleymane Yameogo, Alain Hien, Hélène Peyriere, Olivier Mathieu, Deborah Hirt, Jean-Marc Treluyer, Joëlle Nicolas, Vincent Foulongne, Michel Segondy, Philippe van de Perre, Serge Diagbouga & Philippe Msellati

Volume 89, Number 6, June 2011, 451-458

Table 1. Resistance to lamivudine (3TC), didanosine (DDI) and efavirenz (EFV), ANRS 12103 trial, Bobo-Dioulasso, Burkina Faso, 2006–2007

Patient ID Month of follow-up HIV genotype Mutation positions, NRTI Mutation positions, NNRTI Drug resistance
B03 6 CRF-02 K103N EFV
B05 9 CRF-02 M184I, L210G V90I, K103N, V108I, V179Ia 3TC, EFV
B07 6 CRF-02 L74V, M184V, K219E K103N, K101P 3TC, DDI, EFV
B09 6 CRF-06 M184V K103N, V108I 3TC
B13 6 CRF-02 M184V A106V, G190A, P225H 3TC, EFV
B21 9 CRF-02 M184I K103N, L100I, V179I,a P225H 3TC, EFV
B26 3 CRF-06 M184V K101E, G190E 3TC, EFV
B33 3 CRF-02 M184V K103N 3TC, EFV
B39 12 CRF-02 M184V K103N 3TC, EFV
B44 3 CRF-06 K65R, D67G,a K70E G190E 3TC,b DDI,b EFV
B52 3 CRF-02 K65N,a T215S K103N, M230L EFV

HIV, human immunodeficiency virus; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.

a Polymorphism on known resistance position.

b Likely resistance.